Nova Eye Medical (EYE) Discussion, page-2451

That's the thing, the MIGS market is quite large as it is relative to the current revenue generated by iTrack Advance. Plenty of growth runway in that market alone for us. But the real growth will come from doctors rapidly adopting MIGS treatments as a first line therapy as opposed to drugs (which generate over $6 billion p.a. I believe), and canaloplasty makes the most sense when we're talking about earlier intervention (as it leaves nothing behind and causes no tearing). Cataracts also represent a massive market worth over $10 billion, and so doctors combining iTrack Advance with those also represents a potentially enormous opportunity. Given how easy iTrack Advance is to perform it would really take little effort for doctors to combine the two and it makes a lot of sense as well.

If interventional glaucoma management really kicks off (as appears to be the case now) then the potential TAM will be huge since we will be taking market share from the massive glaucoma drugs market (in addition to the existing surgical market)